CIM
CPRX

Cambria Investment Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Cambria Investment Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$937K Sell
29,813
-105
-0.4% -$3.1K 0.05% 351
2026
Q1 		$741K Buy
29,918
+2,777
+10% +$66.2K 0.04% 281
2025
Q4 		$633K Buy
27,141
+5,424
+25% +$121K 0.04% 342
2025
Q3 		$428K Buy
21,717
+4,338
+25% +$89.2K 0.03% 382
2025
Q2 		$377K Sell
17,379
-482
-3% -$11.4K 0.03% 347
2025
Q1 		$433K Buy
+17,861
New +$402K 0.03% 255

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cambria Investment Management's CPRX Position: Q2 2026 in Review

Cambria Investment Management reduced its Catalyst Pharmaceutical (CPRX) stake by 0.35% in Q2 2026, selling an estimated $3.1K and leaving 29,813 shares worth $937K. The position accounts for 0.05% of the portfolio, ranked #351.

Cambria Investment Management first reported a position in CPRX in Q1 2025 and has held it in 6 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Cambria Investment Management held 29,813 shares of Catalyst Pharmaceutical worth $937K as of Q2 2026.
  • Cambria Investment Management sold 105 Catalyst Pharmaceutical shares in Q2 2026, an estimated $3.1K.
  • Catalyst Pharmaceutical made up 0.05% of Cambria Investment Management's portfolio in Q2 2026, its #351 holding.
  • Cambria Investment Management first reported a position in Catalyst Pharmaceutical in Q1 2025 and has held it in 6 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Cambria Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.